Belite Bio to Participate in Three Upcoming Investor Conferences

August 27, 2025 . 12:14 PM

2 min read

✨ Onyx Summary

Belite Bio announced that its executive team will present at three major upcoming investor conferences in early September, including Cantor, Morgan Stanley, and H.C. Wainwright. Each presentation will be webcast and available for replay on the company’s investor relations website. These appearances highlight growing investor interest as Belite advances Tinlarebant through late-stage trials in Stargardt disease and geographic atrophy, positioning the company at the forefront of developing first-in-class therapies for retinal diseases with no current treatments.

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) – Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details of the presentations are as follows:

Cantor Global Healthcare Conference
- September 5, 2025, at 8:00 am ET, fireside chat
Morgan Stanley 23^rd Annual Global Healthcare Conference
- September 8, 2025, at 5:35 pm ET, fireside chat
H.C. Wainwright 27^th Annual Global Investment Conference
- September 9, 2025, at 8:00 am ET, fireside chat

Webcast Link Instructions

A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.